Pointe Capital Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Pointe Capital Management LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 757 shares of the biopharmaceutical company’s stock, valued at approximately $472,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at about $26,000. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $29,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Finally, Birchwood Financial Partners Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $32,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Truist Financial increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday, July 31st. Citigroup lifted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Canaccord Genuity Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Finally, Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $801.70.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: An analysis titled “Regeneron: Why I Still See Upside After the Rally” reflects a continued bullish view of REGN’s long-term prospects following its recent advance. Regeneron: Why I Still See Upside After the Rally
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day short-interest ratio. However, the figures appear incomplete or erroneous, making them unsuitable as a meaningful trading signal.
• Negative Sentiment: Several law firms publicized a securities-fraud class action tied to Regeneron’s Phase 3 melanoma-therapy trial failure. The trial disclosure reportedly triggered a sharp selloff and erased approximately $11 billion in market value; the lawsuit alleges investors were harmed by inadequate or misleading disclosures. A September 14, 2026 deadline applies to investors seeking lead-plaintiff status. Notices were issued by Hagens Berman, Pomerantz, SueWallSt, and Portnoy Law.
• Negative Sentiment: Additional law firms, including Faruqi & Faruqi, Schall Brown & Schwartz, and Levi & Korsinsky, reiterated the pending litigation and encouraged affected shareholders to participate. The repeated announcements increase near-term legal and reputational overhang, although they do not represent new operating developments. Faruqi & Faruqi notice

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,400 shares of company stock worth $1,090,030. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ REGN opened at $833.56 on Wednesday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $847.00. The firm’s 50-day moving average price is $705.74 and its 200-day moving average price is $717.35. The stock has a market capitalization of $85.82 billion, a price-to-earnings ratio of 20.60, a P/E/G ratio of 1.41 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the business posted $12.81 earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.